Description
Product Usage Information
Western Blotting: 1:1000
Immunoprecipitation: 1:100
Immunofluorescence (Frozen): 1:50 - 1:100
Immunofluorescence (Immunocytochemistry): 1:50 - 1:100
Flow Cytometry (Fixed/Permeabilized): 1:50 - 1:200
Flow Cytometry (Live): 1:50 - 1:200
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 81309 .
Protocol
Available protocols: Western Blotting, Immunoprecipitation, Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized), Flow Cytometry (Live)
Specificity / Sensitivity
TACI/TNFRSF13B/CD267 (E3P6X) Rabbit Monoclonal Antibody recognizes endogenous levels of total TACI/TNFRSF13B/CD267 protein. This antibody is predicted to recognize mulitple isoforms of TACI/TNFRSF13B/CD267.
Species Reactivity: Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of mouse TACI/TNFRSF13B/CD267 protein.
Background
Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) and cluster of differentiation 267 (CD267), is a single-pass type III membrane receptor that is highly expressed on the surface of mature innate-like B cells, such as marginal zone and B-1 B cells in mice, and memory B cells in humans (1-3). TACI/TNFRSF13B/CD267 is also expressed on the surface of activated T cells (4), while monocytes and dendritic cells express lower levels of TACI/TNFRSF13B/CD267 primarily intracellularly (5,6). TACI/TNFRSF13B/CD267 is the receptor for soluble ligands BAFF/TNFSF13B and APRIL/TNFSF13 (7,8). Upon ligation, TACI/TNFRSF13B/CD267 recruits tumor necrosis factor receptor-associated factor (TRAF) family members and calcium signal-modulating cyclophilin ligand (CAMLG) in order to activate NFAT, NF-κB, and AP-1 transcriptional programs (9-11). TACI/TNFRSF13B/CD267 is necessary for T cell-independent type II and type I responses (1,12), negative regulation of B cell and T follicular helper cell numbers (13,14), and promotion of class switch recombination in B cells (15). Mutations and aberrant regulation of TACI/TNFRSF13B/CD267 has been associated with cancer, autoimmune diseases, and immunodeficiency disorders (16-18). Multiple isoforms produced by alternative splicing have been identified.
Alternate Names
1200009E08Rik; CD267; OTTMUSP00000006011; Taci; Tnfrsf13b; TR13B; transmembrane activator and calcium-modulating and cyclophilin ligand interactor; Transmembrane activator and CAML interactor; Tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor superfamily, member 13b
